. . . . . . . . . . . . "[inhibition of HER3 may be more clinically relevant than inhibition of EGFR in HER2-amplified breast cancer and adding pertuzumab to trastuzumab may augment therapeutic benefit by blocking HER2/HER3 signaling]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2009-03-31"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2015-08-25T14:39:17+02:00"^^ . . . . . . . . . . . "v3.0.0.0" . "v3.0.0" .